Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats.
about
Engineered nanomaterial uptake and tissue distribution: from cell to organismInteractions of nanomaterials and biological systems: Implications to personalized nanomedicinePharmaceutical and toxicological properties of engineered nanomaterials for drug deliveryAssessment of the biodistribution of an [(18) F]FDG-loaded perfluorocarbon double emulsion using dynamic micro-PET in rats.Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer modelLiposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures.Platelet-like nanoparticles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries.Effects of PEGylation on the physicochemical properties and in vivo distribution of organic nanotubesNoninvasive detection of passively targeted poly(ethylene glycol) nanocarriers in tumors.Influence of molecular size on the retention of polymeric nanocarrier diagnostic agents in breast ducts.Evaluation of New Fluorescent Lipophosphoramidates for Gene Transfer and Biodistribution Studies after Systemic AdministrationHigher lung accumulation of intravenously injected organic nanotubesToxicodynamics of rigid polystyrene microparticles on pulmonary gas exchange in mice: implications for microemboli-based drug delivery systemsInter-molecular β-sheet structure facilitates lung-targeting siRNA delivery.High azithromycin concentration in lungs by way of bovine serum albumin microspheres as targeted drug delivery: lung targeting efficiency in albino mice.Biodistribution and renal clearance of biocompatible lung targeted poly(ethylene glycol) (PEG) nanogel aggregates.Enhanced passive pulmonary targeting and retention of PEGylated rigid microparticles in ratsGelation chemistries for the encapsulation of nanoparticles in composite gel microparticles for lung imaging and drug deliveryPassive lung-targeted drug delivery systems via intravenous administration.Clinical management of patients receiving cell-based immunoregulatory therapy.Non-spherical micro- and nanoparticles: fabrication, characterization and drug delivery applications.Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.Recent trends on hydrogel based drug delivery systems for infectious diseasesRifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery.Fluorescent dye labeled iron oxide/silica core/shell nanoparticle as a multimodal imaging probe.Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer.(68) Ga-Ca-phytate particles: A potential lung perfusion agent of synthetic origin prepared in a cold kit format.In vivo imaging using polymeric nanoparticles stained with near-infrared chemiluminescent and fluorescent squaraine catenane endoperoxide.Novel monodisperse PEGtide dendrons: design, fabrication, and evaluation of mannose receptor-mediated macrophage targeting.Microfluidic generation of droplets with a high loading of nanoparticlesExploring deformable particles in vascular-targeted drug delivery: Softer is only sometimes better.Passive targeting and lung tolerability of enoxaparin microspheres for a sustained antithrombotic activity in rats.
P2860
Q26861914-EB291996-5A75-4A26-AD2E-F849752E4583Q28391849-B1BFE77D-026C-4215-9A19-BB1FCE9DFCF2Q28396383-58A7D417-586E-4839-9F31-C0358D900872Q30435595-421E65CE-9CE4-42CF-9F17-6BB936472CABQ33517446-EFE79305-3265-487D-A454-2BA486725032Q33608651-11B47AE6-B85A-4568-A884-E6BCE1DC65A5Q34579964-06E12CEC-30D4-4431-B985-ACC239DA71C0Q34731969-A520BDFC-2207-4993-BF68-4FAF68BEAC41Q35671286-E83FE5F6-3BF7-44D9-96DB-DDCA09F9CD6BQ36235198-A28246FE-9BD9-4B69-A335-9AB2570BEF22Q36324477-A1A77EE1-1139-46BB-84B1-C3E101986D22Q36551548-0E72C0ED-A953-4B89-B559-7285070567CFQ36652315-19B075FE-02C2-4A65-94E2-A19197B21297Q36666359-59701016-DF9F-4121-BFF8-6999A2A5C7DCQ36875820-82ECC0ED-253D-48B5-8C65-40C91F1101C2Q37382745-4F896BD6-8474-412B-8B92-91F4C0C7734CQ37550733-4B029E5A-502B-4B74-9FAB-B2EE9D8323C1Q37694016-77B9880F-70A6-44A0-A6D1-835195F5DD41Q38075609-DAFB6BC4-684B-4F9A-B181-6C9F2D68A23FQ38201742-2E56827F-B532-4937-B934-E376C9DBA233Q38261278-5BFA827C-94A6-4D63-BE7D-5C6C7C21C516Q38789348-C3F42B1E-7331-4331-8036-1F19ED7F8BD1Q38810357-77AE418A-32C3-4126-9E30-78BEC54117DBQ38939434-8AD940B7-3989-48C9-B82C-D441425B3686Q38989890-5466B9A7-9E7D-4F90-B3FE-106FC7B3FD1BQ39084250-B6AE52EA-4A18-4B8B-90BF-252C7DA09D2FQ39413283-E8D561CA-3D2B-47CC-83EA-749142C2F5FFQ40018943-A772FBBD-3489-4E35-8844-38A8EF54342CQ41993264-8B024FED-8D32-4817-A301-8A994E1BFC69Q42015913-14095126-7EE1-4A7A-B797-ECA76B3C71A0Q51000739-C32FC2FE-A12E-4CAA-95BE-623984E593E5Q51019109-AE5392FB-1771-4FFC-B678-D019E3A1BB04
P2860
Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Threshold size for optimal pas ...... rigid microparticles in rats.
@ast
Threshold size for optimal pas ...... rigid microparticles in rats.
@en
type
label
Threshold size for optimal pas ...... rigid microparticles in rats.
@ast
Threshold size for optimal pas ...... rigid microparticles in rats.
@en
prefLabel
Threshold size for optimal pas ...... rigid microparticles in rats.
@ast
Threshold size for optimal pas ...... rigid microparticles in rats.
@en
P2093
P2860
P1476
Threshold size for optimal pas ...... rigid microparticles in rats.
@en
P2093
David C Reimer
Debra L Laskin
Hilliard L Kutscher
Laurie B Joseph
Manjeet Deshmukh
Patrick J Sinko
Piyun Chao
Stanley Stein
Yashveer Singh
P2860
P356
10.1016/J.JCONREL.2009.12.019
P407
P577
2010-01-05T00:00:00Z